Type 2 Diabetes Mellitus - quality prescribing strategy: improvement guide 2024 to 2027

References

1. Scottish Intercollegiate Guidelines Network (SIGN), 2017. Pharmacological management of glycaemic control in people with type 2 diabetes. SIGN 154. URL: https://www.sign.ac.uk/sign-116-and-154-diabetes (Accessed: 25 October 2023).

2. National Institute for Health and Clinical Excellence. NICE NG 28 Type 2 diabetes in adults: management. guideline NG 28 (2022 update). 2015. URL: https://www.nice.org.uk/guidance/ng28 (Accessed: 25 October 2023).

3. Davies, M.J., Aroda, V.R., Collins, B.S., Gabbay, R.A., Green, J., Maruthur, N.M., Rosas, S.E., Del Prato, S., Mathieu, C., Mingrone, G. and Rossing, P., 2022. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, pp.1-42 URL: https://link.springer.com/article/10.1007/s00125-022-05787-2 . (Accessed: 25 October 2023)

4. The Scottish Government, Scottish Health Survey 2019, 2020. URL: https://www.gov.scot/binaries/content/documents/govscot/publications/statistics/2020/09/scottish-health-survey-2019-volume-1-main-report/documents/scottish-health-survey-2019-edition-volume-1-main-report/scottish-health-survey-2019-edition-volume-1-main-report/govscot%3Adocument/scottish-health-survey-2019-edition-volume-1-main-report.pdf (Accessed: 25 October 2023).

5. The Scottish Government, Diabetes care - Diabetes improvement plan: commitments - 2021 to 2026, February 2021. URL: https://www.gov.scot/publications/diabetes-improvement-plan-diabetes-care-scotland-commitments-2021-2026/pages/2/#:~:text=In%20our%20commitments%20from%202021%20%E2%80%93%202026%2C%20there,upskilling%20healthcare%20professionals%20remain%20key%20to%20optimising%20outcomes. (Accessed: 25 October 2023).

6. The Scottish Government, A healthier future: Scotland's diet and healthy weight delivery plan. 2018, URL: https://www.gov.scot/publications/healthier-future-scotlands-diet-healthy-weight-delivery-plan/ (Accessed: 25 October 2023).

7. The Scottish Government, A Healthier Future: type 2 Diabetes prevention, early detection and intervention: framework. 2018, URL: https://www.gov.scot/publications/healthier-future-framework-prevention-early-detection-early-intervention-type-2/pages/4/ (Accessed: 25 October 2023).

8. The Scottish Government, Polypharmacy Guidance Realistic Prescribing, 3rd edition 2018, URL: https://www.therapeutics.scot.nhs.uk/wp-content/uploads/2018/04/Polypharmacy-Guidance-2018.pdf (Accessed: 25 October 2023).

9. Realistic Medicine – Shared decision making, reducing harm, waste and tackling unwarranted variation, URL: https://www.realisticmedicine.scot/: (Accessed: 25 October 2023).

10. NHS Scotland, Scottish Diabetes Data Group. Scottish Diabetes Survey 2021. URL: https://www.diabetesinscotland.org.uk/wp-content/uploads/2023/02/Diabetes-Scottish-Diabetes-Survey-2021-final-version.pdf (Accessed: 25 October 2023).

11. Health and Social Care Alliance Scotland Diabetes: my information, my support, 2022, URL: https://www.alliance-scotland.org.uk/wp-content/uploads/2022/08/Diabetes-My-Information-My-Support-Report-August-2022.pdf (Accessed: 25 October 2023).

12. Stedman, M., Lunt, M., Davies, M., Livingston, M., Duff, C., Fryer, A., Anderson, S.G., Gadsby, R., Gibson, M., Rayman, G. and Heald, A., 2020. Cost of hospital treatment of type 1 diabetes (T1DM) and type 2 diabetes (T2DM) compared to the non-diabetes population: a detailed economic evaluation. BMJ open, 10(5), p.e033231. URL: https://bmjopen.bmj.com/content/bmjopen/10/5/e033231.full.pdf (Accessed: 25 October 2023)

13. Department of Health and Social Care, Good for you, good for us, good for everybody, 2021, URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1019475/good-for-you-good-for-us-good-for-everybody.pdf (Accessed: 25 October 2023).

14. Royal Pharmaceutical Society, Sustainability Policy, 2021, URL: https://www.rpharms.com/recognition/all-our-campaigns/policy-a-z/pharmacys-role-in-climate-action-and-sustainable-healthcare (Accessed: 25 October 2023).

15. Royal College of General Practitioners Council Motion, Sustainable development, climate change and green issues, 2019, URL: https://www.rcgp.org.uk/policy/rcgp-policy-areas/climate-change-sustainable-development-and-health (Accessed: 25 October 2023).

16. CAN, H.C.I.P.C., Decarbonising Patient Care Pathways. URL: https://a.storyblok.com/f/109506/x/88fe7ea368/smi-hstf-pcp-whitepaper.pdf (Accessed: 25 October 2023)

17. Wilkinson, J.L., Boxall, A.B., Kolpin, D.W., Leung, K.M., Lai, R.W., Galbán-Malagón, C., Adell, A.D., Mondon, J., Metian, M., Marchant, R.A. and Bouzas-Monroy, A., 2022. Pharmaceutical pollution of the world’s rivers. Proceedings of the National Academy of Sciences, 119(8), p.e2113947119. URL: https://www.pnas.org/doi/epdf/10.1073/pnas.2113947119 (Accessed: 25 October 2023)

18. The Scottish Government. Chief Medical Officer for Scotland Annual Report 2020 - 2021 Recover, Restore, Renew. URL: https://www.gov.scot/binaries/content/documents/govscot/publications/corporate-report/2021/03/cmo-annual-report-2020-21/documents/chief-medical-officer-scotland-annual-report-2020-2021/chief-medical-officer-scotland-annual-report-2020-2021/govscot%3Adocu (Accessed: 25 October 2023)

19. Trautwein, C et al. Occurrence of the antidiabetic drug Metformin and its ultimate transformation product Guanylurea in several compartments of the aquatic cycle. Environment International Vol 70, Sept 2014, pp203-212, URL: https://www.sciencedirect.com/science/article/abs/pii/S0160412014001512 (Accessed 1st June 2023)

20. Ambrosio-Albuquerquev EP et al, Metformin environmental exposure: a systematic review. Environmental Toxicology and Pharmacology Vol 83, April 2021, 103588, URL: https://www.sciencedirect.com/science/article/abs/pii/S1382668921000077 (Accessed: 25 October 2023)

21. World Health Organization. The world health report 2008: primary health care now more than ever. World Health Organization, 2008,URL: https://apps.who.int/iris/bitstream/handle/10665/43949/9789241563734_eng.pdf?sequence=1&isAllowed=y (Accessed: 25 October 2023).

22. Barnett, K., Mercer, S.W., Norbury, M., Watt, G., Wyke, S. and Guthrie, B., 2012. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. The Lancet, 380(9836), pp.37-43. URL: https://pubmed.ncbi.nlm.nih.gov/22579043/ (Accessed: 25 October 2023).

23. Ornstein, S.M., Nietert, P.J., Jenkins, R.G. and Litvin, C.B., 2013. The prevalence of chronic diseases and multimorbidity in primary care practice: a PPRNet report. The Journal of the American Board of Family Medicine, 26(5), pp.518-524. URL: https://www.jabfm.org/content/26/5/518 (Accessed: 25 October 2023).

24. Boyd, C.M. and Fortin, M., 2010. Future of multimorbidity research: how should understanding of multimorbidity inform health system design? Public health reviews, 32(2), pp.451-474. URL: https://publichealthreviews.biomedcentral.com/articles/10.1007/BF03391611 (Accessed: 25 October 2023).

25. World Health Organization, 2003. Adherence to long-term therapies: evidence for action. World Health Organization. URL: https://apps.who.int/iris/bitstream/handle/10665/42682/9241545992.pdf (Accessed: 25 October 2023).

26. Nguyen, T.L., Leguelinel-Blache, G., Kinowski, J.M., Roux-Marson, C., Rougier, M., Spence, J., Le Manach, Y. and Landais, P., 2017. Improving medication safety: development and impact of a multivariate model-based strategy to target high-risk patients. PloS one, 12(2), p.e0171995. URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0171995 (Accessed: 25 October 2023).

27. Picco, L., Achilla, E., Abdin, E., Chong, S.A., Vaingankar, J.A., McCrone, P., Chua, H.C., Heng, D., Magadi, H., Ng, L.L. and Prince, M., 2016. Economic burden of multimorbidity among older adults: impact on healthcare and societal costs. BMC health services research, 16(1), pp.1-12. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4862090/ (Accessed: 25 October 2023).

28. The Scottish Government, Person-centred Care: What Non-Executive Members Can Do, 2019, URL: https://www.gov.scot/binaries/content/documents/govscot/publications/advice-and-guidance/2019/11/person-centred-care-non-executive-members/documents/person-centred-care-non-executive-members/person-centred-care-non-executive-members/govscot%3Adocument/person-centred-care-non-executive-members.pdf (Accessed: 25 October 2023).

29. Health and Social Care Alliance Scotland, The House of Care Model, URL: https://www.alliance-scotland.org.uk/health-and-social-care-integration/house-of-care/house-of-care-model/ (Accessed: 25 October 2023).

30. Stratton, I.M., Adler, A.I., Neil, H.A.W., Matthews, D.R., Manley, S.E., Cull, C.A., Hadden, D., Turner, R.C. and Holman, R.R., 2000. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ, 321(7258), pp.405-412, URL: https://www.bmj.com/content/321/7258/405.full.pdf+html (Accessed: 25 October 2023).

31. American Diabetes Association, 2021. 6. Glycemic targets: standards of medical care in diabetes—2021. Diabetes Care, 44(Supplement_1), pp.S73-S84. URL: https://diabetesjournals.org/care/article/44/Supplement_1/S73/30909/6-Glycemic-Targets-Standards-of-Medical-Care-in (Accessed: 25 October 2023).

32. Knowler, W.C., 2002. Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med, 346, pp.393-403. URL: https://pubmed.ncbi.nlm.nih.gov/11832527/ (Accessed: 25 October 2023).

33. Lean, M.E., Leslie, W.S., Barnes, A.C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., Hollingsworth, K.G. and Rodrigues, A.M., 2018. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. The Lancet, 391(10120), pp.541-551. URL: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)33102-1/fulltext (Accessed: 25 October 2023).

34. Riddle, M.C., Cefalu, W.T., Evans, P.H., Gerstein, H.C., Nauck, M.A., Oh, W.K., Rothberg, A.E., le Roux, C.W., Rubino, F., Schauer, P. and Taylor, R., 2022. Consensus report: definition and interpretation of remission in type 2 diabetes. The Journal of Clinical Endocrinology & Metabolism, 107(1), pp.1-9. URL: https://academic.oup.com/jcem/article/107/1/1/6358623 (Accessed: 25 October 2023).

35. McCombie, L., Leslie, W., Taylor, R., Kennon, B., Sattar, N. and Lean, M.E., 2017. Beating type 2 diabetes into remission. BMJ, 358. URL: https://www.bmj.com/content/358/bmj.j4030 (Accessed: 25 October 2023).

36. Holman, R.R., Paul, S.K., Bethel, M.A., Matthews, D.R. and Neil, H.A.W., 2008. 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine, 359(15), pp.1577-1589. URL: https://www.nejm.org/doi/full/10.1056/nejmoa0806470 (Accessed: 25 October 2023).

37. Maruthur, N.M., Tseng, E., Hutfless, S., Wilson, L.M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J.B. and Bolen, S., 2016. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Annals of internal medicine, 164(11), pp.740-751. URL: https://www.acpjournals.org/doi/full/10.7326/M15-2650 (Accessed: 25 October 2023).

38. Aroda, V.R., Edelstein, S.L., Goldberg, R.B., Knowler, W.C., Marcovina, S.M., Orchard, T.J., Bray, G.A., Schade, D.S., Temprosa, M.G., White, N.H. and Crandall, J.P., 2016. Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. The Journal of Clinical Endocrinology & Metabolism, 101(4), pp.1754-1761. URL: https://academic.oup.com/jcem/article/101/4/1754/2804585 (Accessed: 25 October 2023).

39. National Institute for Health and Clinical Excellence - Joint Formulary Committee. British national formulary, Prescribing in renal impairment, 2022, URL: https://bnf.nice.org.uk/medicines-guidance/prescribing-in-renal-impairment/ (Accessed: 25 October 2023).

40. American Diabetes Association, 2021. 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes—2021. Diabetes care, 44(Supplement_1), pp.S111-S124, URL: https://diabetesjournals.org/care/article/44/Supplement_1/S111/31020/9-Pharmacologic-Approaches-to-Glycemic-Treatment (Accessed: 25 October 2023).

41. Sinclair A, Gallagher A. Managing frailty and associated comorbidities in older adults with diabetes: Position Statement on behalf of the Association of British Clinical Diabetologists (ABCD). 2019, URL: https://abcd.care/sites/abcd.care/files/site_uploads/Resources/Position-Papers/ABCD-Position-Paper-Frailty.pdf (Accessed: 25 October 2023).

42. Cosentino, F., Grant, P.J., Aboyans, V., Bailey, C.J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D.E., Hansen, T.B. and Huikuri, H.V., 2020. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). European heart journal, 41(2), pp.255-323, URL: https://academic.oup.com/eurheartj/article/41/2/255/5556890 (Accessed: 25 October 2023).

43. Caparrotta, T.M., Blackbourn, L.A., McGurnaghan, S.J., Chalmers, J., Lindsay, R., McCrimmon, R., McKnight, J., Wild, S., Petrie, J.R., Philip, S. and McKeigue, P.M., 2020. Prescribing paradigm shift? Applying the 2019 European Society of Cardiology–led guidelines on diabetes, prediabetes, and cardiovascular disease to assess eligibility for sodium–glucose cotransporter 2 inhibitors or glucagon-like peptide 1 receptor agonists as first-line monotherapy (or Add-on to Metformin Monotherapy) in type 2 diabetes in Scotland. Diabetes Care, 43(9), pp.2034-2041.

44. National Institute for Health and Clinical Excellence. NICE CG181 Cardiovascular disease: risk assessment and reduction, including lipid modification, URL: https://www.nice.org.uk/guidance/cg181/resources/cardiovascular-disease-risk-assessment-and-reduction-including-lipid-modification-pdf-35109807660997 (Accessed: 25 October 2023).

45. Medicines and Healthcare products Regulatory Agency, 2016. SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis. Drug Safety Update, 9(9), p.1. URL: https://www.gov.uk/drug-safety-update/sglt2-inhibitors-updated-advice-on-the-risk-of-diabetic-ketoacidosis (Accessed: 25 October 2023).

46. UK, G., 2020. SGLT2 inhibitors: monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness. Drug Safety Update, 13(8). URL: https://www.gov.uk/drug-safety-update/sglt2-inhibitors-monitor-ketones-in-blood-during-treatment-interruption-for-surgical-procedures-or-acute-serious-medical-illness (Accessed: 25 October 2023).

47. US Food and Drug Administration, FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections, 2020, URL: https://www.fda.gov/drugs/drug-safety-and-availability/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about-too-much-acid-blood-and-serious (Accessed: 25 October 2023).

48. National Institute for Health and Clinical Excellence. NICE NG 203 Chronic kidney disease: assessment and management, 2021, URL: https://www.nice.org.uk/guidance/ng203/resources/chronic-kidney-disease-assessment-and-management-pdf-66143713055173 (Accessed: 25 October 2023).

49. Healthcare Improvement Scotland, Scottish Health Technologies Group, Advice Statement: Freestyle Libre® flash glucose monitoring 2018, URL: https://shtg.scot/our-advice/freestyle-libre-flash-glucose-monitoring/ (Accessed: 25 October 2023).

50. Strain, W.D., Hope, S.V., Green, A., Kar, P., Valabhji, J. and Sinclair, A.J., 2018. Type 2 diabetes mellitus in older people: a brief statement of key principles of modern day management including the assessment of frailty. A national collaborative stakeholder initiative. Diabetic Medicine, 35(7), pp.838-845. URL: https://onlinelibrary.wiley.com/doi/full/10.1111/dme.13644 (Accessed: 25 October 2023).

51. Rockwood, K., Song, X., MacKnight, C., Bergman, H., Hogan, D.B., McDowell, I. and Mitnitski, A., 2005. A global clinical measure of fitness and frailty in elderly people. Cmaj, 173(5), pp.489-495. URL: https://www.dal.ca/sites/gmr/our-tools/clinical-frailty-scale.html (Accessed: 25 October 2023).

52. Lunghi, C., Zongo, A., Moisan, J., Gregoire, J.P. and Guénette, L., 2017. The impact of incident depression on medication adherence in patients with type 2 diabetes. Diabetes & metabolism, 43(6), pp.521-528. URL: https://www.sciencedirect.com/science/article/abs/pii/S1262363617304767 (Accessed: 25 October 2023).

53. De Groot, M., Anderson, R., Freedland, K.E., Clouse, R.E. and Lustman, P.J., 2001. Association of depression and diabetes complications: a meta-analysis. Psychosomatic medicine, 63(4), pp.619-630. URL: https://pubmed.ncbi.nlm.nih.gov/11485116/ (Accessed: 25 October 2023).

54. NHS Scotland. Scottish Diabetes Group Short Life Working Group on Mental Health Screening in Diabetes, URL: https://diabetespsychologymatters.files.wordpress.com/2022/04/sdg-swlg-mental-health-screening-and-associated-care-pathways-2022.pdf (Accessed 25 October 2023).

55. Vancampfort, D., Correll, C.U., Galling, B., Probst, M., De Hert, M., Ward, P.B., Rosenbaum, S., Gaughran, F., Lally, J. and Stubbs, B., 2016. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta‐analysis. World Psychiatry, 15(2), pp.166-174. URL: https://onlinelibrary.wiley.com/doi/full/10.1002/wps.20309 (Accessed: 15 October 2023).

56. Nielsen, R.E., Banner, J. and Jensen, S.E., 2021. Cardiovascular disease in patients with severe mental illness. Nature Reviews Cardiology, 18(2), pp.136-145. URL: https://www.nature.com/articles/s41569-020-00463-7#Abs1 (Accessed: 15 October 2023).

57. Darwish, L., Beroncal, E., Sison, M.V. and Swardfager, W., 2018. Depression in people with type 2 diabetes: current perspectives. Diabetes, metabolic syndrome and obesity: targets and therapy, 11, p.333. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6044353/ (Accessed: 15 October 2023).

58. Ducat, L., Rubenstein, A., Philipson, L.H. and Anderson, B.J., 2015. A review of the mental health issues of diabetes conference. Diabetes care, 38(2), pp.333-338. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302262/ (Accessed: 15 October 2023).

59. Holt, R.I., 2019. Association between antipsychotic medication use and diabetes. Current diabetes reports, 19(10), pp.1-10. URL: https://link.springer.com/article/10.1007/s11892-019-1220-8 (Accessed: 15 October 2023).

60. Penninx, B.W. and Lange, S.M., 2022. Metabolic syndrome in psychiatric patients: overview, mechanisms, and implications. Dialogues in clinical neuroscience. URL: https://www.tandfonline.com/doi/full/10.31887/DCNS.2018.20.1/bpenninx (Accessed: 15 October 2023).

61. Reddy, P., Philpot, B., Ford, D. and Dunbar, J.A., 2010. Identification of depression in diabetes: the efficacy of PHQ-9 and HADS-D. British Journal of General Practice, 60(575), pp.e239-e245. URL: https://pubmed.ncbi.nlm.nih.gov/20529487/ (Accessed: 15 October 2023).

62. The Scottish Government, Mental Health in Scotland: Improving the Physical Health and Well Being of those Experiencing Mental Illness. 2006, URL: https://www.gov.scot/publications/mental-health-scotland-improving-physical-health-well-being-those-experiencing-mental-illness/ (Accessed: 15 October 2023).

63. Williamson, E.J., Walker, A.J., Bhaskaran, K., Bacon, S., Bates, C., Morton, C.E., Curtis, H.J., Mehrkar, A., Evans, D., Inglesby, P. and Cockburn, J., 2020. Factors associated with COVID-19-related death using OpenSAFELY. Nature, 584(7821), pp.430-436. URL: https://www.nature.com/articles/s41586-020-2521-4 (Accessed: 15 October 2023).

64. Goff, L.M., 2019. Ethnicity and type 2 diabetes in the UK. Diabetic Medicine, 36(8), pp.927-938. URL: https://onlinelibrary.wiley.com/doi/full/10.1111/dme.13895 (Accessed: 15 October 2023).

65. Tillin, T., Hughes, A.D., Godsland, I.F., Whincup, P., Forouhi, N.G., Welsh, P., Sattar, N., McKeigue, P.M. and Chaturvedi, N., 2013. Insulin resistance and truncal obesity as important determinants of the greater incidence of diabetes in Indian Asians and African Caribbeans compared with Europeans: the Southall And Brent REvisited (SABRE) cohort. URL: https://diabetesjournals.org/care/article/36/2/383/38145/Insulin-Resistance-and-Truncal-Obesity-as (Accessed: 15 October 2023).

66. Paul, S.K., Owusu Adjah, E.S., Samanta, M., Patel, K., Bellary, S., Hanif, W. and Khunti, K., 2017. Comparison of body mass index at diagnosis of diabetes in a multi‐ethnic population: A case‐control study with matched non‐diabetic controls. Diabetes, Obesity and Metabolism, 19(7), pp.1014-1023. URL: https://dom-pubs.onlinelibrary.wiley.com/doi/full/10.1111/dom.12915 (Accessed: 15 October 2023).

67. Zeh, P., Sandhu, H.K., Cannaby, A.M. and Sturt, J.A., 2014. Cultural barriers impeding ethnic minority groups from accessing effective diabetes care services: a systematic review of observational studies. Diversity and Equality in Health and Care, 11(1), pp.9-33. URL: https://www.primescholars.com/articles/cultural-barriers-impeding-ethnic-minority-groups-from-accessing-effective-diabetes-care-services-a-systematic-review-of-94511.html (Accessed: 15 October 2023).

68. The Scottish Government, Trauma-Informed Practice: A Toolkit for Scotland, 2021, URL: https://www.gov.scot/publications/trauma-informed-practice-toolkit-scotland/pages/4/ (Accessed: 15 October 2023).

69. The Scottish Government, Digital health and care strategy, 2021, URL: https://www.gov.scot/publications/scotlands-digital-health-care-strategy/documents/ (Accessed: 15 October 2023).

70. Scottish Government Effective Prescribing and Therapeutics Division and Public Health Scotland, 2023. National Therapeutic Indicators URL: https://scotland.shinyapps.io/nhs-prescribing-nti/ (Accessed 19 October 2023)